MedTrace Logo

Health Evaluation in African Americans Using RAS Therapy

NCT02471833 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-05-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease prevention in African Americans, who are at high risk for Alzheimer's disease.

Conditions

Interventions

DRUG

Telmisartan 20mg

Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

DRUG

Telmisartan 40mg

Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

DRUG

Placebo

Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Whitney Whitney, PhD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2022-04-15
Completion
2022-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02471833 on ClinicalTrials.gov